Rabbit ATG for aplastic anaemia treatment: A backward step?

The Lancet

Volumn 378, Issue 9806, 2011, Pages 1831-1833

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; THYMOCYTE ANTIBODY;

APLASTIC ANEMIA; CANCER COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NOTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 82255191839     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60817-9     Document Type: Note

References (13)

1. JC Marsh, SE Ball, J Cavenagh et al. Guidelines for the diagnosis and management of aplastic anaemia Br J Haematol 147 2009 43 70
2. Scheinberg P, Wu CO, Scheinberg P, et al. A randomized trial of horse versus rabbit antithymocyte globulin in severe acquired aplastic anemia. ASH Annual Meeting Abstracts; Orlando, FL, USA; Dec 4-7, 2010: LBA-4 (abstr).
3. A Tichelli, H Schrezenmeier, G Socie et al. A randomized controlled study in newly-diagnosed severe aplastic anemia patients receiving antithymocyte globulin, ciclosporin, with or without G-CSF Blood 117 2011 4434 4441
4. MG Afable, M Shaik, Y Sugimoto et al. Efficacy of rabbit antithymocyte globulin in severe aplastic anemia Haematologica 2011 10.3324/haematol.2011. 042622 published online May 23.
5. EA Atta, DS Dias, VLN Marra, AM de Azevedo Comparison between horse and rabbit antithymocyte globulin as first line treatment for patients with severe aplastic anemia: a single centre retrospective study Ann Hematol 89 2010 851 859
6. CJM Halkes, A Brand, PA von dem Borne et al. Increasing the dose of rabbit-ATG does not lead to a higher response rate in the first-line treatment of severe aplastic anaemia Bone Marrow Transplant 46 suppl 2011 S373
7. T Kadia, F Ravandi, G Garcia-Manero et al. Updated results of combination cytokine immunotherapy in the treatment of aplastic anaemia and myelodysplastic syndrome (MDS) Blood 116 suppl 2010 2920 (abstr).
8. Marsh J, Socie G, Tichelli A, et al, on behalf of the EBMT Severe Aplastic Anaemia (SAA) Working Party. Prospective phase 2 pilot study of rabbit antithymocyte globulin with ciclosporin for patients with acquired aplastic anaemia and matched pair analysis with patients treated with horse ATG and ciclosporin. 37th Annual Meeting of the European Group for Blood and Marrow Transplantation; Paris, France; April 3-6, 2011: 208 (abstr).
9. P Saracco, A Lorenzati, R Oneto on behalf of the AIEOP Bone Marrow Failure Study Group Italian registry of pediatric acquired aplastic anaemia: a retrospective study Bone Marrow Transplant 46 suppl 2011 S374
10. C Vallejo, P Montesinos, A Rosell et al. Comparison between lymphoglobuline- and thymoglobuline-based immunosuppressive therapy as first-line treatment for patients with aplastic anemia Blood 114 suppl 2009 3194 (abstr).
11. AM Risitano, C Selleri, B Serio on behalf of the Working Party Severe Aplastic Anemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT) Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA Br J Haematol 148 2009 791 796
12. A Bacigalupo, G Socie, E Lanino on behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party Haematologica 95 2010 976 982
13. JC Marsh, V Gupta, Z Lim et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia Blood 2011 10.1182/blood-2010-12-327536 published online April 25.